Trials / Completed
CompletedNCT04236960
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
Phase I Clinical Study of Meningococcal Group ACYW135 Conjugate Vaccine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Walvax Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Months – 55 Years
- Healthy volunteers
- Accepted
Summary
A single-center and open-labeled Phase I study, designed to evaluate the safety by observing the occurrence of adverse events and change of hematology, liver and renal function after vaccination of a meningococcal group A, C, Y, and W135 conjugate vaccine in healthy population aged 2 months to 55 years old.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal Group ACYW135 Conjugate Vaccine | 1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos) |
Timeline
- Start date
- 2018-07-17
- Primary completion
- 2019-09-16
- Completion
- 2019-11-28
- First posted
- 2020-01-22
- Last updated
- 2020-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04236960. Inclusion in this directory is not an endorsement.